HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates PGEN, TCMD Investors, Encourages Investors with Losses to Contact Firm, Reminds of Critical Upcoming Deadlines
SAN FRANCISCO, Oct. 19, 2020 (GLOBE NEWSWIRE) — Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided.
Precigen, Inc. (PGEN) Securities Fraud Class Action:
The complaint alleges that Defendants misrepresented and concealed that: (1) the Company was using pure methane as feedstock for its announced yields for its methanotroph bioconversion (“MCB”) platform instead of natural gas; (2) yields from natural gas as a feedstock were substantially lower than the announced pure methane yields; (3) due to the substantial price difference between pure methane and natural gas, pure methane was not a commercially viable feedstock; (4) the Company’s 1Q 2018 financial statements were false; (5) the Company had material weaknesses in its internal controls over financial reporting; and (6) the Company was under investigation by the SEC since October 2018.
Investors allegedly began to learn the truth through a series of disclosures beginning on Aug. 9, 2018, when the company announced that its 1Q 2018 financial results could no longer be relied on. In its restated 1Q 2018 results, the company made significant changes to deferred revenue, collaboration and licensing revenues and accumulated deficit, as well as admitted to material weaknesses in its internal controls over financial reporting.
Then, on Mar. 2, 2020, the company disclosed it received a subpoena in Oct. 2018 from the SEC concerning Precigen’s MCB-related disclosures.
Finally, on Sept. 25, 2020, the SEC issued a cease and desist order involving “inaccurate reports concerning the company’s purported success converting relatively inexpensive natural gas into more expensive industrial chemicals using a proprietary [MCB] program.”
“We’re focused on investors’ losses and proving that Precigen cooked its books and promoted fake technology,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you are a Precigen investor and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman.
Hagens Berman’s Tactile Securities Litigation:
Throughout the Class Period, Defendants allegedly misrepresented and concealed that: (1) while Tactile publicly touted a $4 plus billion or $5 plus billion market opportunity, in truth, the total addressable market for Tactile’s medical devices was materially smaller; (2) to induce sales growth and share gains, Tactile engaged in illegal sales and marketing activities; and (3) Tactile’s revenues were in part the product of unlawful conduct and thus unsustainable.
The truth began to emerge on Mar. 20, 2019, when an amended federal Qui Tam complaint filed against Tactile was unsealed, which contained detailed allegations of illegal sales practices on the part of Tactile, causing the Company to submit fraudulent claims to Medicare and the VA.
Then, on Feb. 21, 2020, the court issued an order in the Qui Tam Action, denying Tactile’s motion to dismiss in its entirety.
Finally, on June 8, 2020, research firm OSS Research published a scathing report about the Company, accusing Tactile of using a “‘daisy-chaining’ kickback scheme that has resulted in rampant overprescribing and rapid market share gains at the expense of patients, insurers and the public.”
All told, these disclosures caused Tactile securities to decline precipitously, wiping out significant shareholder value.
If you are a TCMD investor, click here to discuss your legal rights with Hagens Berman. A copy of the Complaint can be obtained here.
“We’re focused on investors’ losses and proving Tactile deceived investors by engaging in illegal marketing schemes to induce sales growth,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
Whistleblowers: Persons with non-public information regarding Precigen and/or Tactile should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844–916–0895 or email [email protected] and/or [email protected].
About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Reed Kathrein, 844-916-0895
Originally Published on : http://www.globenewswire.com/news-release/2020/10/19/2110744/0/en/HAGENS-BERMAN-NATIONAL-TRIAL-ATTORNEYS-Updates-PGEN-TCMD-Investors-Encourages-Investors-with-Losses-to-Contact-Firm-Reminds-of-Critical-Upcoming-Deadlines.html
Contact/WhatsAPP: +91 7827887720 EMAIL: [email protected]
Disclaimer: The perspectives communicated in the article/news/press release above are those of the writers’ and don’t really speak to or mirror the perspectives of this website or its personnel. Except if in any case noticed, the writer is writing in his/her own ability. They are not expected and ought not to be thought to speak to legitimate thoughts, perspectives, or strategies of any individual, Institution, organization or foundation.